Page last updated: 2024-10-25

citalopram and Movement Disorders

citalopram has been researched along with Movement Disorders in 6 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.

Research Excerpts

ExcerptRelevanceReference
" A selective serotonergic drug (citalopram) or a placebo was administered using a mean dosage of 10 mg/day in combination with physiotherapy."2.74A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. ( Acler, M; Fiaschi, A; Manganotti, P; Robol, E, 2009)
"Citalopram-induced LA was dose-dependently attenuated by the 5-HT1B/1D receptor antagonists, S18127, GR125,743 and GR127,935, and by the selective 5-HT1B antagonist, SB224,289, but unaffected by the selective 5-HT1A antagonist, WAY100,635."1.32Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. ( Brocco, M; Girardon, S; Millan, MJ; Veiga, S, 2003)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nowidi, K1
Kunisch, R1
Bouna-Pyrrou, P1
Meißner, D1
Hennig-Fast, K1
Weindl, A1
Förster, S1
Neuhann, TM1
Falkai, P1
Berger, M1
Musil, R1
Acler, M1
Robol, E1
Fiaschi, A1
Manganotti, P1
Rozzini, L1
Chilovi, BV1
Conti, M1
Bertoletti, E1
Zanetti, M1
Trabucchi, M1
Padovani, A1
Birthi, P1
Walters, C1
Karandikar, N1
Algahtani, HA1
Seddeq, YA1
Alfudhail, AM1
Abdu, A1
Millan, MJ1
Veiga, S1
Girardon, S1
Brocco, M1

Trials

1 trial available for citalopram and Movement Disorders

ArticleYear
A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients.
    Journal of neurology, 2009, Volume: 256, Issue:7

    Topics: Administration, Oral; Aged; Brain; Citalopram; Dominance, Cerebral; Double-Blind Method; Evoked Pote

2009

Other Studies

5 other studies available for citalopram and Movement Disorders

ArticleYear
[The White man's burden - a case study caught between bipolar affective disorder and Huntington's disease].
    Fortschritte der Neurologie-Psychiatrie, 2013, Volume: 81, Issue:6

    Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Citalopram; Dibenzothiazepines; Femal

2013
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
    International psychogeriatrics, 2010, Volume: 22, Issue:1

    Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr

2010
A rare case of tardive dyskinesia and akathisia induced by citalopram.
    PM & R : the journal of injury, function, and rehabilitation, 2010, Volume: 2, Issue:10

    Topics: Adult; Akathisia, Drug-Induced; Citalopram; Humans; Male; Movement Disorders; Selective Serotonin Re

2010
A young women who couldn't see or move.
    Neurosciences (Riyadh, Saudi Arabia), 2011, Volume: 16, Issue:1

    Topics: Adolescent; Basal Ganglia; Cerebral Cortex; Citalopram; Coma; Female; Hemoglobins; Humans; Magnetic

2011
Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.
    Psychopharmacology, 2003, Volume: 168, Issue:4

    Topics: Animals; Citalopram; Environment Design; Fluvoxamine; Injections, Subcutaneous; Male; Mice; Motor Ac

2003